tiprankstipranks
Arcturus Therapeutics (ARCT)
NASDAQ:ARCT
US Market
ARCT
Arcturus Therapeutics
RESEARCH TOOLSreports
Want to see ARCT full AI Analyst Report?

Arcturus Therapeutics (ARCT) Stock News & Sentiment

2,168 Followers
Arcturus Therapeutics’ Earnings Call: mRNA Bets vs. Burn
Premium
Company Announcements
Arcturus Therapeutics’ Earnings Call: mRNA Bets vs. Burn
6d ago
ARCT
Myles Minter Reiterates Buy on Arcturus Therapeutics, Highlighting Long-Term Upside Despite More Conservative Near-Term Outlook
Premium
Ratings
Myles Minter Reiterates Buy on Arcturus Therapeutics, Highlighting Long-Term Upside Despite More Conservative Near-Term Outlook
7d ago
ARCT
ARCT Rating Reiterated at Hold as High-Risk ARCT-032 CF Program Awaits Binary Phase 2 Readout; $9 Price Target Maintained
Premium
Ratings
ARCT Rating Reiterated at Hold as High-Risk ARCT-032 CF Program Awaits Binary Phase 2 Readout; $9 Price Target Maintained
13d ago
ARCT
Arcturus Therapeutics Signals Progress Amid Revenue Slip
Premium
Company Announcements
Arcturus Therapeutics Signals Progress Amid Revenue Slip
17d ago
ARCT
Myles Minter Reiterates Buy on Arcturus, Citing Strengthened CF Pipeline, Reduced Competitive Pressure, and Rare-Disease Upside
Premium
Ratings
Myles Minter Reiterates Buy on Arcturus, Citing Strengthened CF Pipeline, Reduced Competitive Pressure, and Rare-Disease Upside
18d ago
ARCT
Arcturus Therapeutics Reports Q1 Results, Advances Rare Disease Pipeline
Premium
Company Announcements
Arcturus Therapeutics Reports Q1 Results, Advances Rare Disease Pipeline
18d ago
8K
ARCT
ARCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
Premium
Pre-Earnings
ARCT Earnings Report this Week: Is It a Buy, Ahead of Earnings?
21d ago
ARCT
More ARCT News >

ARCT News on the Web

Arcturus Therapeutics’ Earnings Call: mRNA Bets vs. Burn
TipRanks News
Neutral
Myles Minter Reiterates Buy on Arcturus Therapeutics, Highlighting Long-Term Upside Despite More Conservative Near-Term Outlook
TipRanks News
Bullish
ARCT Rating Reiterated at Hold as High-Risk ARCT-032 CF Program Awaits Binary Phase 2 Readout; $9 Price Target Maintained
TipRanks News
Neutral
Analysts Offer Insights on Healthcare Companies: DocGo (DCGO), Arcturus Therapeutics (ARCT) and Waters (WAT)
TipRanks News
Neutral
Arcturus Therapeutics Signals Progress Amid Revenue Slip
TipRanks News
Bullish
Arcturus Therapeutics (ARCT) Gets a Buy from Canaccord Genuity
TipRanks News
Bullish
Myles Minter Reiterates Buy on Arcturus, Citing Strengthened CF Pipeline, Reduced Competitive Pressure, and Rare-Disease Upside
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: Arcturus Therapeutics (ARCT), Celldex (CLDX) and Collegium Pharmaceutical (COLL)
TipRanks News
Neutral

News Score - Last 7 Days

Very Positive
ARCT
Sector Average
Media Buzz
This Week2 articles
Weekly Average2.75 articles
News Sentiment
This Week100%
Sector Average80%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is ARCT’s Media Buzz Sentiment?
2 articles about ARCT were published this week. In an average week, 2.75 articles are published.
    What is ARCT’s weekly average amount of articles?
    In an average week, 2.75 articles about ARCT are published.
      What is ARCT’s News Sentiment?
      100% of articles about ARCT were positive this week, compared to its sector average of 80%.
        Healthcare Stocks that are Trending in the News
        RLAYRelay Therapeutics
        ROIVRoivant Sciences
        TLSATiziana Life Sciences
        JUNSJupiter Neurosciences, Inc.
        IMMXImmix Biopharma
        Showing the stocks with the most bullish news sentiment over the past week